Result of AGM
June 08 2006 - 7:13AM
UK Regulatory
RNS Number:2637E
VASTox plc
08 June 2006
VASTox plc ("VASTox" or "the Company")
RESULT of AGM
VASTox (AIM: VOX), a leading chemical genomics company, is pleased to announce
that all of the resolutions at the AGM of the Company, held today, were duly
passed.
8 June 2006
For more information please contact:
VASTox Tel: +44 (0)1235 443910
Steven Lee, PhD, Chief Executive Officer
Darren Millington, Chief Financial Officer
Citigate Dewe Rogerson Tel: +44 (0)207 638 9571
David Dible / Mark Swallow / Valerie Auffray
About VASTox
VASTox is a chemical genomics technology company that discovers and develops
proprietary novel drugs and provides services to the pharmaceutical industry.
The company's most advanced drug development programme is focused on developing
a new treatment for Duchenne muscular dystrophy based on the up-regulation of
utrophin. A second drug development programme for spinal muscular atrophy is
also progressing rapidly. VASTox has three additional programmes focused on
osteoarthritis, cancer and tuberculosis that are expected to be out-licensed
prior to entering the clinic.
The company's technology platform, which uses zebrafish and fruitflies, has the
potential to dramatically decrease the time and cost of drug discovery and
development. This is because using whole organisms allows it to carry out high
volume, high content screening that delivers data which is highly predictive of
the efficacy and toxicity of potential drug compounds in humans. VASTox is
growing revenues based on marketing its unique technology platform and its
chemistry expertise. The company listed on the AIM market of the London Stock
Exchange in October 2004.
This information is provided by RNS
The company news service from the London Stock Exchange
END
RAGSSEFFASMSEFM
Vox Valor Capital (LSE:VOX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Vox Valor Capital (LSE:VOX)
Historical Stock Chart
From Jul 2023 to Jul 2024